share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Eisenstadt Richard I

SEC announcement ·  Feb 2 07:02
Summary by Futu AI
Richard I Eisenstadt, the Chief Financial Officer of Altimmune, Inc. [ALT], completed a series of transactions involving the company's common stock over the course of January 30 and January 31, 2024. On January 30, Eisenstadt exercised options to acquire 9,275 shares at no cost and subsequently sold 2,175 shares at $9.80 per share, resulting in a total market value of $21,315. The following day, he acquired an additional 4,621 shares at $2.69 per share through a grant or award. After these transactions, Eisenstadt's direct holdings in Altimmune increased to a total of 45,012 shares of common stock.
Richard I Eisenstadt, the Chief Financial Officer of Altimmune, Inc. [ALT], completed a series of transactions involving the company's common stock over the course of January 30 and January 31, 2024. On January 30, Eisenstadt exercised options to acquire 9,275 shares at no cost and subsequently sold 2,175 shares at $9.80 per share, resulting in a total market value of $21,315. The following day, he acquired an additional 4,621 shares at $2.69 per share through a grant or award. After these transactions, Eisenstadt's direct holdings in Altimmune increased to a total of 45,012 shares of common stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.